Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domain
SARS-CoV-2 S2 도메인에 대한 항체의 결합 및 중화 능력
Article
Published on
Journal: Human vaccines & immunotherapeutics
[Category] COVID19(2023년), MERS, SARS, 변종, 진단,
Journal: Human vaccines & immunotherapeutics
[Category] COVID19(2023년), MERS, SARS, 변종, 진단,
[키워드] acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
antibodies
antibody
B.1.1.7
B.1.351
B.1.617.2
B.1.621
binding
binding activity
carried
conserved
convalescent patient
coronavirus
coronavirus 2
coronavirus disease
Coronavirus disease 2019
COVID-19
determined by
domain
ELISA
enzyme
enzyme-linked immunosorbent
enzyme-linked immunosorbent assay
evaluated
Evidence
Immune escape
immune protection
mAb
mAbs
MERS
MERS-CoV
Middle East
Middle East respiratory syndrome
Middle East respiratory syndrome Coronavirus
molecular
monoclonal antibodies
monoclonal antibody
N Terminal
N terminal domain
NAbs
Neutralization assay
neutralization assay.
Neutralizing
Neutralizing activity
Neutralizing antibodies
neutralizing antibody
NTD
P.1
Protein
pseudo-virus
RBD
Receptor binding domain
reported
Research
respiratory
Result
S protein
S proteins
S2 protein
S2 subunit
SARS-CoV
SARS-CoV-2
SARS-CoV-2 RBD
SARS-CoV-2 S
SARS-CoV-2 S2
SARS-CoV-2 WT
Severe acute respiratory syndrome
severe acute respiratory syndrome Coronavirus
significantly
specific antibodies
subunit
target
targets
terminal
Vaccine design
variant
variants
wild-type
[DOI] 10.1080/21645515.2022.2055373 PMC 바로가기 [Article Type] Article
[DOI] 10.1080/21645515.2022.2055373 PMC 바로가기 [Article Type] Article